PE anti-human CD62L Antibody
- 产品名称：
- PE anti-human CD62L Antibody
- 产品类别：
- 抗体
- 产品编号：
- 304805
- 产品应用：
- 304805
[价格]
| 规格 |
价格 |
库存 |
| 25tests |
￥ 1372 |
1 |
- Verified Reactivity
- Human
- Reported Reactivity
- Chimpanzee, Cow
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- Concentrated supernatant from PMA-activated human peripheral blood leukocytes
- Formulation
- ?g size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA). - Preparation
- The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
- Concentration
- ?g sizes: 0.2 mg/mLtest sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the ?g size, the suggested use of this reagent is ≤0.125 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Application Notes
Additional reported applications (for the relevant formats) include: Western blotting2,3,9 and in vitro blocking of lymphocytes binding to high endothelial venules (HEV)2. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. Nos. 304853-304858).
- Application References
(PubMed link indicates BioLegend citation) -
- Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
- Kishimoto TK, et al. 1990. Proc. Natl. Acad. Sci. USA 87:2244. (WB, Block)
- Jutila M, et al. 2002. J. Immunol. 169:1768. (WB)
- Tamassia N, et al. 2008. J. Immunol. 181:6563. (FC) PubMed
- Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
- Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
- Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
- Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- Koenig JM, et al. 1996. Pediatr. Res. 39:616. (WB)
- Shi C, et al. 2011. J. Immunol. 187:5293. (FC) PubMed
- Burges M, et al. 2013. Clin Cancer Res. 19:5675. PubMed
- Cash JL, et al. 2013. EMBO Rep. 14:999. (FC) PubMed
- Product Citations
-
- Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
- Liu B, et al. 2015. J Virol. 89: 11834 - 11844. PubMed
- Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
- Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
- Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
- Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
- Jones N, et al. 2021. Nat Commun. 12:1209. PubMed
- Sung BY, et al. 2022. J Clin Invest. 132:. PubMed
- Hug S, et al. 2021. Front Immunol. 12:642867. PubMed
- Gatla H, et al. 2022. Front Med Technol. 4:850565. PubMed
- Wu D, et al. 2020. Biomark Res. 8:3. PubMed
- Carnevale J, et al. 2022. Nature. 609:174. PubMed
- Sureshchandra S, et al. 2021. iScience. 24:102690. PubMed
- Velázquez–Avila M, et al. 2019. Leukemia. 33:1337. PubMed
- Magri G et al. 2017. Immunity. 47(1):118-134 . PubMed
- Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
- Ye Z, et al. 2021. Nat Commun. 12:907. PubMed
- He Z, et al. 2016. Exp Hematol. 44:161-165. PubMed
- Burgess M, et al. 2013. Clin Cancer Res. 19:5675. PubMed
- Seery V, et al. 2021. EBioMedicine. 67:103357. PubMed
- Bonte S, et al. 2021. Oncoimmunology. 10:1954800. PubMed
- Lima J, et al. 2016. Reprod Sci. 10.1177/1933719116653680. PubMed
- Uniken Venema WT, et al. 2019. Gastroenterology. 156:812. PubMed
- Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
- Ye Z, et al. 2021. NPJ Aging Mech Dis. 7:4. PubMed
- Fan Z, et al. 2020. STAR Protoc. 1:100012. PubMed
- Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
- Tokatlian T, et al. 2022. J Immunother Cancer. 10:. PubMed
- Messerer DAC, et al. 2020. Front Immunol. 11:571992. PubMed
- Wu B, et al. 2022. Nat Commun. 13:2155. PubMed
- Johnson AJ, et al. 2021. Cancer Immunol Res. 9:1047. PubMed
- Groen B, et al. 2015. Sci Rep. 5: 13618. PubMed
- Anderson NR, et al. 2019. Cell Adh Migr. 13:163. PubMed
- RRID
- AB_314465 (BioLegend Cat. No. 304805) AB_2564163 (BioLegend Cat. No. 304840) AB_314466 (BioLegend Cat. No. 304806)
- Structure
- Selectin, single chain glycoprotein, 74-95 kD
- Distribution
-
Majority of B cells, na?ve T cells, subset of memory T and NK cells, monocytes, granulocytes, thymocytes
- Function
- Leukocyte homing, leukocyte tethering, rolling
- Ligand/Receptor
- CD34, GlyCAM, MAdCAM-1
- Cell Type
- B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Thymocytes, Tregs
- Biology Area
- Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
- Molecular Family
- Adhesion Molecules, CD Molecules
- Antigen References
-
- Kishimoto T, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
- Kishimoto T, et al. 1991. Blood 78:805.
?
- Gene ID
- 6402 View all products for this Gene ID
- UniProt
- View information about CD62L on UniProt.org
